mAbxience |

BIO INTERNATIONAL CONVENTION

04/09/2019

BIO INTERNATIONAL CONVENTION, to be held 3-6 June in Philadelphia, PA.

Mundo Sano launches “Not a Single Baby with Chagas” initiative to change the history of Chagas disease

03/14/2019

“Not a Single Baby with Chagas” is a reflection of the Foundation’s commitment to ensuring that by 2030 all babies born with Chagas disease can be treated and cured, and that all women of reproductive age have access to diagnosis and treatment. Every hour, a baby is born somewhere in the world with Chagas disease. […]

Meet us at BIO-EUROPE SPRING and 17th BIOSIMILAR MEDICINES CONFERENCE

03/12/2019

Meet us at BIO-EUROPE SPRING and 17th BIOSIMILAR MEDICINES CONFERENCE, to be held 25-27 March in Vienna and 28-29 March in Amsterdam.

A 3D-printed human skin dressing, a migraine predictor and a smart insulin pen: the three startups selected for support by Insud Pharma

02/18/2019

BioDan, a 3D dressing derived from human skin which can be bioprinted and frozen, Brainguard, a wearable system that predicts migraines, and Insulclock, a system which monitors and controls the treatment of diabetes patients are the three startups selected in the second round of the ChemoStart accelerator programme, which seeks to support innovative, disruptive solutions […]

Twelve startups present disruptive healthcare solutions at Insud Pharma’s Pitch Day

01/30/2019

• The ChemoStart Programme is an initiative by Insud Pharma, spearheaded by Leandro Sigman, to support innovative healthcare startups   • In the second edition of the programme, 12 finalists have been shortlisted to present to a panel of experts at the Pitch Day on Thursday 31 January Madrid, 30 January 2019.- Insud Pharma’s startup […]

Publication of the final data from the clinical trial for mAbxience bevacizumab in metastatic colorectal cancer published in The Lancet Gastroenterology & Hepatology

09/27/2018

The prestigious scientific journal The Lancet Gastroenterology and Hepatology journal has published the results of the comparative study of pharmacokinetics, efficacy, safety and immunogenicity of bevacizumab biosimilar BEVZ92 in combination with FOLFOX or FOLFIRI, as the first-line treatment for metastatic colorectal cancer versus the original reference product.  The trial included 15 sites from 5 countries, […]